Glucagon Injection 1 mg, occupies a distinctive and important position in the field of human digestive regulation. Among its many physiological functions, one core function is the precise regulation of gastric peristalsis rhythm to slow gastric emptying, thereby indirectly modulating the efficiency of intestinal glucose absorption and achieving refined management of the digestive process. This dedicated digestive control function is fundamentally different from its previously discussed clinical applications in emergency treatment and examination assistance. It does not involve critical illness rescue nor does it assist in complex gastrointestinal examination procedures. Instead, it focuses on the synergistic regulation of daily digestion and metabolism, playing an irreplaceable and important role in maintaining metabolic balance and ensuring stable digestive function. This provides solid support for the body's normal energy metabolism and digestive physiological activities.
Our Products Description
Glucagon COA
 |
||
| Certificate of Analysis | ||
| Compound name | Glucagon | |
| Grade | Pharmaceutical grade | |
| CAS No. | 16941-32-5 | |
| Quantity | 38g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202501090088 | |
| MFG | Jan 9th 2025 | |
| EXP | Jan 8th 2028 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.54% |
| Loss on drying | ≤1.0% | 0.42% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.90% |
| Single impurity | <0.8% | 0.52% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Keep in dark place,Sealed in dry,2-8°C | |
|
|
||
|
|
||
| Chemical Formula | C153H225N43O49S |
| Exact Mass | 3480.62 |
| Molecular Weight | 3482.80 |
| m/z | 3481.62 (100.0%), 3482.62 (82.2%), 3480.62 (60.4%), 3483.63 (26.5%), 3483.63 (18.2%), 3484.63 (18.1%), 3482.62 (15.9%), 3483.62 (13.1%), 3483.62 (10.1%), 3481.61 (9.6%), 3484.63 (8.3%), 3482.62 (6.1%), 3485.63 (5.2%), 3483.61 (4.5%), 3484.62 (4.2%), 3484.62 (3.7%), 3484.62 (2.9%), 3482.61 (2.7%), 3485.63 (2.7%), 3482.63 (2.4%), 3483.63 (2.0%), 3482.62 (1.9%), 3485.63 (1.8%), 3485.63 (1.8%), 3484.62 (1.6%), 3483.63 (1.5%), 3481.62 (1.5%), 3485.62 (1.3%), 3483.61 (1.2%), 3485.62 (1.2%), 3486.64 (1.1%), 3486.63 (1.1%), 3481.62 (1.1%), 3485.63 (1.1%), 3484.62 (1.0%) |
| Elemental Analysis | C, 52.76; H, 6.51; N, 17.29; O, 22.51; S, 0.92 |
Smoothing the Rhythm of Glucose Absorption and Reducing Absorption Fluctuations
As a vital energy source for the body, glucose absorption rates that are either too rapid or too slow can impact metabolic stability. By slowing gastric emptying, it effectively regulates the rate at which glucose enters the intestine, thereby reducing its absorption rate and delivering significant metabolic benefits:
Glucagon injection 1 mg Prevents Sharp Increases in Glucose Absorption, Reducing Metabolic Pressure: Under normal circumstances, carbohydrates are rapidly digested in the stomach after a meal and then enter the intestine for absorption. This can lead to a sudden surge in glucose absorption within a short period, placing instantaneous stress on the body's metabolic system. By delaying the transit of gastric contents into the intestine, this allows glucose to enter the intestine and be absorbed in batches, slowly. This avoids excessively high absorption peaks, reduces the burden on the metabolic system, and makes the glucose absorption process smoother and more orderly.
Maintaining Glucose Absorption Homeostasis and Ensuring Sustained Energy Supply: Slowing gastric emptying and reducing the absorption rate does not mean decreasing the total amount of glucose absorbed; rather, it prolongs the absorption cycle. This regulatory mechanism allows glucose to be absorbed and utilized by the body at a steady rate over a longer period. It avoids the extremes of "excess energy from excessively rapid absorption" and "energy deficiency from excessively slow absorption," achieving glucose absorption homeostasis. This provides the body with continuous and stable energy support, adapting to daily metabolic demands.
Optimizing the Digestive Process and Enhancing Digestive Comfort
Glucagon's role in digestive control not only regulates glucose absorption but also indirectly optimizes the overall digestive process, enhancing the body's digestive comfort. The specific benefits are as follows:
1. Coordinating Digestive Rhythm to Adapt to the Body's Metabolic State
The body's digestive rhythm is not fixed but dynamically adjusts according to changes in the body's metabolic state and physiological scenarios. A close synergistic relationship exists between the two. If the digestive rhythm becomes disconnected from metabolic demands, issues such as digestive disorders and energy metabolism imbalance can arise.Through precise regulation of the gastric emptying rate and glucose absorption rate, it achieves an accurate adaptation of the digestive rhythm to the body's metabolic state, ensuring the digestive process consistently aligns with the body's energy needs.For example, in scenarios where the metabolic rate is slower, such as during sleep or periods of prolonged sitting, the body's energy consumption decreases.
Here, glucagon appropriately slows the gastric emptying rate and reduces the efficiency of glucose absorption, preventing excessive glucose from being absorbed and then stored as fat due to untimely consumption, thereby reducing metabolic burden. Conversely, during routine daily activities when metabolic demands are relatively stable, this maintains a steady gastric emptying and glucose absorption rhythm. This ensures glucose is absorbed and utilized by the body at a consistent rate, providing continuous and stable energy support for various physiological activities and preventing issues like fatigue or dizziness caused by insufficient energy supply. This dynamic coordination effectively enhances the overall digestive experience, maintains the balance between digestion and metabolism, and places the body in a more comfortable and healthier physiological state.
2. Slowing Gastric Emptying Rate and Reducing Stomach Burden
An excessively rapid gastric emptying rate is a common cause of gastric discomfort and digestive stress. When gastric contents are rapidly propelled into the intestine, not only does the stomach quickly become empty, leading to noticeable hunger pangs, dull gastric pain, or acid reflux, but food may also enter the intestine without adequate preliminary digestion in the stomach. This means incompletely broken-down macromolecules enter the intestine, increasing the digestive burden on the intestines and potentially triggering intestinal motility disorders, resulting in issues such as bloating, abdominal pain, diarrhea, or difficulty with bowel movements.
By precisely regulating the peristaltic rhythm of the gastric smooth muscle, glucagon effectively slows the rate of gastric emptying. This allows food to remain in the stomach for a longer period, fully mixing with digestive juices secreted by the stomach, such as gastric acid and pepsin, to complete the initial digestive breakdown process. This transforms macromolecular food into smaller molecules that are more easily absorbed by the intestine. This regulatory mechanism not only reduces muscle fatigue caused by frequent gastric peristalsis, lessening the physiological burden on the stomach, but also diminishes the irritation of inadequately digested food on the intestine. Consequently, it effectively reduces the occurrence of digestive discomfort symptoms like bloating and abdominal pain, making the gastric digestion process smoother and more efficient.
Assisting Metabolic Regulation and Providing Support for Metabolic Health
The digestive control function of glucagon is essentially an indirect regulation of the body's metabolism. The benefits it brings provide strong support for overall metabolic health, specifically reflected in the following:
Glucagon injection 1 mg can Adapt to Digestive Demands Under Different Physiological States:** The body's demand for glucose and its digestive capacity vary across different physiological states. The digestive control function of it possesses a certain adaptability, allowing it to fine-tune the gastric emptying rate and glucose absorption rate according to the body's condition. This meets the digestive and metabolic needs in different scenarios, further optimizing the metabolic regulatory effect.
It Reduces the Impact of Glucose Absorption Fluctuations on Metabolism: Drastic fluctuations in glucose absorption can easily lead to metabolic disturbances, and over the long term, may affect metabolic balance. By smoothing the rhythm of glucose absorption, this reduces the interference of such fluctuations on the metabolic system, helping to maintain metabolic homeostasis and laying the foundation for the body's metabolic health.
In summary, through its core digestive control function of slowing gastric emptying and reducing the glucose absorption rate, it can smooth the rhythm of glucose absorption, alleviate metabolic pressure, optimize the digestive process, enhance digestive comfort, and assist in maintaining metabolic homeostasis, thereby supporting the body's metabolic health. Although this function does not involve emergency diagnosis and treatment scenarios, it plays a non-negligible role in daily metabolic regulation. Its application value is primarily reflected in the synergistic regulation of digestion and metabolism.
Dosage Form Optimization to Enhance Convenience and Applicability:
In the future, targeted research and optimization of glucagon injection 1 mg dosage forms will address the limitations of existing formulations. For example, optimizing the administration method of emergency this by developing more convenient inhalable or sublingual dosage forms to replace traditional injections. This would reduce the operational difficulty for non-professionals, allowing family members to administer the medication quickly and safely in emergency situations. Simultaneously, for gastrointestinal examination formulations, long-acting or sustained-release dosage forms could be developed to prolong the duration of intestinal smooth muscle relaxation, adapting to longer, more complex gastrointestinal examinations and further improving examination efficiency.
Expansion of Application Scenarios to Explore Potential Clinical Value:
Building upon the two existing core applications, future research will delve deeper into glucagon's mechanism of action to explore its application potential in more clinical scenarios. For instance, investigating its use in conditions such as intestinal spastic abdominal pain and postoperative intestinal function recovery could provide new ideas and solutions for treating these conditions. Concurrently, integrating the concept of precision medicine, research into individualized application protocols for it in different populations (such as the elderly, children, and patients with chronic diseases) will enhance the specificity and safety of its use.
Deepening Research on Combination Therapies and Mechanisms to Improve Diagnostic and Therapeutic Outcomes:
Future efforts will strengthen research on the combined use of this with other medications, exploring its synergistic effects with gastrointestinal examination adjuncts and emergency drugs to further enhance diagnostic and therapeutic outcomes. At the same time, in-depth investigation into the specific molecular mechanisms by which this relaxes intestinal smooth muscle and provides emergency relief for hypoglycemia will provide a more solid theoretical foundation for drug development and dosage optimization. This will promote more scientific, precise, and efficient application of it in clinical practice.
FAQ
- Is metformin a glucagon-like peptide-1?
Metformin reduces plasma glucose and has been shown to increase glucagon-like peptide 1 (GLP-1) secretion. Whether this is a direct action of metformin on GLP-1 release, and whether some of the glucose-lowering effect of metformin occurs due to GLP-1 release, is unknown.
- Do type 2 diabetics need glucagon?
The American Diabetes Association recommends that all patients at risk for hypoglycemia be prescribed it. Despite this recommendation, there is evidence that prescription rates are lower than expected for patients with type 1 and type 2 diabetes.
Hot Tags: Glucagon Injection 1 mg, China Glucagon Injection 1 mg manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, dulaglutide how to inject, glp1 shot, etelcalcetide structure
